support

# Expert Assessment: Closed-Loop tACS Targeting EC-II SST Interneurons in Alzheimer's Disease

## Translational Feasibility Analysis

### 1. Target Druggability Assessment

**SST as a molecular target** is well-characterized with five GPCR subtypes (SSTR1-5) and FDA-approved analogs (octreotide, pasireotide). However, the hypothesis operates at the *circuit level* rather than targeting SST signaling directly—the therapeutic lever is **modulating SST+ interneuron activity** to restore inhibitory tone.

**Critical considerations:**
- **Cell-type specificity** is the central druggability challenge. tACS lacks single-cell resolution; even closed-loop approaches cannot selectively recruit EC-II SST interneurons without affecting adjacent excitatory neurons and other inhibitory populations.
- **Anatomical depth** poses a fundamental constraint—the entorhinal cortex lies 2-4 cm from the scalp surface, where current density falls by ~80-90%.
- **Molecular pathways** connecting SST interneuron activity to tau propagation remain mechanistically underspecified. The claim that disinhibition "allows" tau propagation requires demonstrated causative links, not merely correlative disruption.

| Target Component | Druggability Rating | Key Limitation |
|------------------|---------------------|----------------|
| SST receptor signaling | High | CNS penetration of analogs poor; systemic effects |
| SST+ interneuron activity | Moderate | tACS lacks cell-type specificity |
| EC-II microcircuit | Low | Anatomical inaccessibility |
| Tau propagation pathway | Low | Mechanism undefined |

### 2. Tool Compounds and Experimental Assets

**Existing tools:**

| Tool Category | Specific Agents | Translational Readiness |
|---------------|-----------------|------------------------|
| **Electrical stimulation** | tACS/t